Drug intelligence / Profile preview

BIOSC-1

Development stage: Preclinical
Lead developer: Allegro
Modality: Cell Therapies

Overview

BIOSC-1 is a preclinical-stage Advanced Therapy Medicinal Product (ATMP) being developed by Allegro (Allegro.bio). It is the lead candidate from the company's BIOSC platform, which focuses on bio-scaffold technology for tissue engineering and regenerative medicine. As an ATMP, BIOSC-1 is designed to repair, replace, or regenerate human tissue, although specific therapeutic indications and molecular targets have not been publicly disclosed. The program is currently in the preclinical phase of development and represents a novel approach to regenerative therapy using engineered scaffolds.

Beyond the preview

Go deeper on BIOSC-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOSC-1.

Explore the full profile